The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Open accessAbstract
Chronic myelogenous leukemia (CML) arises from the constitutive activity of the BCR-ABL1 oncoprotein. Tyrosine kinase inhibitors (TKIs) that target the ATP-binding site have transformed CML into a chronic manageable disease. However, some patients develop drug resistance due to ATP-site mutations impeding drug binding. We describe the discovery of asciminib (ABL001), the first allosteric BCR-ABL1 inhibitor to reach the clinic. Asciminib binds to the myristate pocket of BCR-ABL1 and maintains activity against TKI-resistant ATP-site mutations. Although resistance can emerge due to myristate-site mutations, these are sensitive to ATP-competitive inhibitors so that combinations of asciminib with ATP-competitive TKIs suppress the emergence of resistance. Fragment-based screening using NMR and X-ray yielded ligands for the myristate pocket. An NMR-based conformational assay guided the transformation of these inactive ligands into ABL1 inhibitors. Further structure-based optimization for potency, physicochemical, pharmacokinetic, and drug-like properties, culminated in asciminib, which is currently undergoing clinical studies in CML patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Iqbal, Z., Aleem, A., Iqbal, M., Naqvi, M. I., Gill, A. T., Taj, A. S., Qayyum, A., ur-Rehman, N., Khalid, A. M., Shah, I. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055717 · Cited by 44
RetractedHamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00656997 · Cited by 18,436
Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds
Miyaura, N., & Suzuki, A. (1995) · Chemical Reviews · doi:10.1021/cr00039a007 · Cited by 12,817
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Self-citationComprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879
The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias
Epstein, F. H., Kurzrock, R., Gutterman, J. U., & Talpaz, M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810133191506 · Cited by 837
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 614
Self-citationTargeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
Zhang, J., Adrián, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., et al. (2010) · Nature · doi:10.1038/nature08675 · Cited by 597
Self-citationStudying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507
Palladium-Catalysed Reactions of Organotin Compounds
Mitchell, T. N. (1992) · Synthesis · doi:10.1055/s-1992-26230 · Cited by 491
A Myristoyl/Phosphotyrosine Switch Regulates c-Abl
Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., & Superti-Furga, G. (2003) · Cell · doi:10.1016/s0092-8674(03)00191-0 · Cited by 480
Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 433
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio760 · Cited by 381
Self-citationABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity
Colicelli, J. (2010) · Science Signaling · doi:10.1126/scisignal.3139re6 · Cited by 347
Ponti, F. D., Poluzzi, E., Cavalli, A., Recanatini, M., & Montanaro, N. (2002) · Drug Safety · doi:10.2165/00002018-200225040-00004 · Cited by 309
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Cowan-Jacob, S. W., Fendrich, G., Floersheimer, A., Furet, P., Liebetanz, J., Rummel, G., Rheinberger, P., Centeleghe, M., Fabbro, D., & Manley, P. W. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906047287 · Cited by 296
Self-citationEvaluation of gastrointestinal drug supersaturation and precipitation: Strategies and issues
Bevernage, J., Brouwers, J., Brewster, M. E., & Augustijns, P. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.11.026 · Cited by 250
Ba/F3 cells and their use in kinase drug discovery
Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a25f · Cited by 240
Self-citationExtended kinase profile and properties of the protein kinase inhibitor nilotinib
Manley, P. W., Drueckes, P., Fendrich, G., Furet, P., Liebetanz, J., Martiny-Baron, G., Mestan, J., Trappe, J., Wartmann, M., & Fabbro, D. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.11.008 · Cited by 225
Self-citationGintant, G. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.08.008 · Cited by 222
Library Design for Fragment Based Screening
Schuffenhauer, A., Ruedisser, S., Marzinzik, A., Jahnke, W., Selzer, P., & Jacoby, E. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026054637700 · Cited by 203
Self-citationChronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
Jabbour, E., & Kantarjian, H. (2016) · American Journal of Hematology · doi:10.1002/ajh.24275 · Cited by 183
Miura, M. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00103 · Cited by 163
Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery
Jahnke, W., Rondeau, J., Cotesta, S., Marzinzik, A. L., Pellé, X., Geiser, M., Strauss, A., Götte, M., Bitsch, F., Hemmig, R., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.421 · Cited by 129
Self-citationJahnke, W., Grotzfeld, R. M., Pellé, X., Strauss, A., Fendrich, G., Cowan‐Jacob, S. W., Cotesta, S., Fabbro, D., Furet, P., Mestan, J., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja101837n · Cited by 123
Self-citationYang, J., Campobasso, N., Biju, M. P., Fisher, K. E., Pan, X.-Q., Cottom, J., Galbraith, S., Ho, T. F., Zhang, H., Hong, X., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.12.013 · Cited by 113
Kubonishi, I., & Miyoshi, I. (1983) · The International Journal Of Cell Cloning · doi:10.1002/stem.5530010205 · Cited by 112
Part II: Management of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70379-0 · Cited by 111
QPatch: the past, present and future of automated patch clamp
Mathes, C. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.2.319 · Cited by 106
Mirams, G. R., Davies, M. R., Brough, S. J., Bridgland-Taylor, M. H., Cui, Y., Gavaghan, D. J., & Abi‐Gerges, N. (2014) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2014.07.002 · Cited by 100
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
Fabbro, D., Manley, P. W., Jahnke, W., Liebetanz, J., Szyttenholm, A., Fendrich, G., Strauss, A., Zhang, J., Gray, N. S., Adrián, F., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.009 · Cited by 64
Self-citationExpanding the Diversity of Allosteric Bcr-Abl Inhibitors
Deng, X., Barun, O., Ding, Q., Zhang, J., Choi, Y., Adrián, F., Wojciechowski, A., Zhang, G., Che, J., Bursulaya, B. D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100555f · Cited by 59
Self-citationXu, Y., Brenning, B., Kultgen, S. G., Foulks, J. M., Clifford, A., Lai, S., Chan, A., Merx, S., McCullar, M. V., Kanner, S. B., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500300c · Cited by 59
Laneuville, P., DiLea, C., Yin, O. Q. P., Woodman, R. C., Mestan, J., & Manley, P. W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4945 · Cited by 54
Self-citationSecond-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy
Kantarjian, H. M., Baccarani, M., Jabbour, E. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2922 · Cited by 54
Metabolic Stability Assessed by Liver Microsomes and Hepatocytes
Ackley, D. C., Rockich, K. T., & Baker, T. R. (2004) · Humana Press eBooks · doi:10.1385/1-59259-800-5:151 · Cited by 36
High-throughputinvitroprofiling assays: lessons learnt from experiences at Novartis
Faller, B., Wang, J., Zimmerlin, A. G., Bell, L., Hamon, J., Whitebread, S., Azzaoui, K., Bojanic, D., & Urbán, L. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.823 · Cited by 33
Update on emerging treatments for chronic myeloid leukemia
Fava, C., Morotti, A., Dogliotti, I., Saglio, G. N., & Rege‐Cambrin, G. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1031217 · Cited by 27
Caco‐2 and Emerging Alternatives for Prediction of Intestinal Drug Transport: A General Overview
Artursson, P., & Tavelin, S. (2003) · Methods and principles in medicinal chemistry · doi:10.1002/3527601473.ch4 · Cited by 23
Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia
Manley, P. W., & Stiefl, N. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_5 · Cited by 15
Self-citationAnagnostou, T., & Litzow, M. R. (2017) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s130197 · Cited by 13
Cited by
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Self-citationMolecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902328 · Cited by 471
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Metadata
- Authors
- Schoepfer, J., Jahnke, W., Berellini, G., Buonamici, S., Cotesta, S., Cowan-Jacob, S. W., Dodd, S., Drueckes, P., Fabbro, D., Gabriel, T., Groell, J.-M., Grotzfeld, R. M., Hassan, A. Q., Henry, C., Iyer, V., Jones, D., Lombardo, F., Loo, A., Manley, P. W., Pellé, X., Rummel, G., Salem, B., Warmuth, M., Wylie, A. A., Zoller, T., Marzinzik, A. L., & Furet, P.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-08-23
- Volume
- 61
- Issue
- 18
- Pages
- 8120-8135
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2888514087
- Cited by
- 454
- References
- 47
- FWCI
- 17.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.